SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment

By HEOR Staff Writer

January 30, 2023

Paxlovid COVID-19 Treatment

SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.

International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.

Reference url

Recent Posts

medtech market access strategy
Prioritizing a Comprehensive Medtech Market Access Strategy Through Stakeholder Engagement

By João L. Carapinha

June 9, 2026

An effective medtech market access strategy must begin at the concept stage by simultaneously addressing patient needs, clinical workflows, regulatory requirements, and payer expectations rather than defaulting to FDA clearance as the sole priority. Startups that ignore this broader view risk bui...
FDA Approval Hemophilia Treatment
Advancing Hemophilia Treatment through FDA Approval of Innovative Prophylaxis

By João L. Carapinha

June 9, 2026

FDA Approval Hemophilia Treatment expands meaningful choices for people with hemophilia A and hemophilia B whose needs have long exceeded available therapies. Pfizer’s HYMPAVZI (marstacimab-hncq) now offers a once-weekly subcutaneous non-factor option to adults and adolescents 12 years and older ...
HIV Weekly Treatment Options
Potential for Advancements in HIV Weekly Treatment Options

By João L. Carapinha

June 9, 2026

HIV Weekly Treatment Options took a major step forward as Gilead and Merck reported that their investigational once-weekly combination of islatravir and lenacapavir successfully met the primary endpoint in two Phase 3 trials. The oral regimen maintained viral suppression in adults already control...